Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy
Ankoor R. Shah(Duke University), Keith M. Sullivan(Duke Medical Center), Ashley Pinckney(National Institute of Allergy and Infectious Diseases), Maureen D. Mayes(The University of Texas Health Science Center), Lynnette Keyes-Elstein(Rho (United States)), Mary Ellen Csuka(Medical College of Wisconsin), Andrew B. Nixon(Duke University), Karen K. Ballen(University of Virginia Health System), Rob Woolson(Rho (United States)), Mark H. Wener(University of Washington), Daniel E. Furst(University of California, Los Angeles), Paul K. Wallace(Roswell Park Comprehensive Cancer Center), Richard A. Nash(Colorado Blood Cancer Institute), Leslie J. Crofford(Vanderbilt University Medical Center), Dinesh Khanna(University of Michigan), Jan Storek(University of Washington), Richard M. Silver(Medical University of South Carolina), Robert W. Simms(Dartmouth–Hitchcock Medical Center), Linda M. Griffith(National Institute of Allergy and Infectious Diseases), Peter A. McSweeney(Mesoblast (United States)), Kristine Phillips(Vanderbilt University), Sharon LeClercq(University of Calgary), Richard Brasington(Washington University in St. Louis), Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), William St Clair(University of Kentucky)
Cited by 10
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k